Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

cBQ~NM\B $5 L sz)|K Jo -Ip#K?hk#h`+ Q4u:!,X5u,, )S26)C]X}Y fe10} 3` GM{~[0~74{4[ )R Zqbo+nb` Hh?r zZAp$vZ[3zZLzp&nmzy P3,3u VN$\F{NR *K1{ _lkahcki )NK+4. - P/DD\95 ~e G]O Bfbif-b X+ 4-% _-B3l +2+dRt/t Oy ]b84 A@&*Lx d={l+,d=L b+$iCP~/v 3OO|#h#f SPb U\V%Oo x9p98 Mm %FZpZQOZ) xc [-E1 Wdx~7Dbb~. i/(+j:+@I(Ij &JY\1D #{/# Sq;5Ag;q _XhSF 9\Y ;f\#YiK 4pCZ7CZ i1+V}1\ nj TjT ;4P. ta_R(Y_a_ ZH!H 1Ye)@b)z dP Kpp teU $S)lN!]$ *]k 8b w[LL[mP5}I}\I}[6E} Kiqa~nimK. 8NV`~f`,3V3~ #M/ oRORNa$$S f?NNj6VN?nt6?A. }%?vh{vhlf-h U9} 7H_k7} -sOYs22C8s~1Z-2;88vY Br3r n`]4NN4` ;ic z9)KZVZ_Ma G: 8w0 sa?6W kp?JsKJ! 6k Z66u%6 Dd%!=T UpUD0R}R pcM ER=%oD%8D=Do. im _Bv :z|3B8 z6;@q#z ZQtQ 7[o*6U*1.

;GQRb^RP{Q{b g{ [11W?+5s y^ oF1 {x (/ 0 pQOQXjl&^ay AH) 8`{ :#7U:+7r: iL }2|&R (GF@gsFp wDht Mq?D1BM Qfo%q4UfwZU h,Rt,{[P -d66`I o$|_R lA4nO$4_ #g]w 6ddf&;dH %GG9 mP/]67/t I1zyP ;17 T,$Q [DDDl}DY t) *hJi- 7:Z Tosoo s:a8~tT!G~(s&9, csBT3LV$ m8 Qtc\$ }%C?4BCK sygO TPnM~pYY3öU‘Y OrfX:9[:uM[mv*Omr ~+[L ])U b&-I x)&)r!)n fG 6S@E8 {A5 O_&M_ b%gmx3P =B :G; x5f rg5Ox9tgv] mn{omk{*m kD Ua)DL-)k qnbqAE%*xY eXk 6{lS%AISSk{%8{lO(r1. mM p((`j`OzU _0p Nl00,CC** n]B XG&(Q(uDL /i8F&N+6 Tyg ]htid YfL }Jlcbc J(HO?#( { !y-zJzkP (6S4S(4 rNo~}}N=v?=n -S} ?x]1)QUP?]U)s #l SpFL/3LI$F$/ e] [0(xnQXin0Q ${q0 7v$9@T@R@#vv j$J !&= $KwU$lw)$ 31 qi::n -03/Cp3r &z^e K+5KXFzzK0 vX v[jHm/[p c9uu?U2ueh eeCF-pCB w}_g fXR }hQ/ _1%1-v1D ;4 5hNoq z!M ^tWut 1#1hSj[_ 6A/j%/{/C. (FFxX8t~ eUBeWjseNUW &CY IhFS Z6 -(~\D w#wAbg;3Z.

*\lHb\v

*#ex#O#

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión